Redwood granted Catalent exclusive rights to market antibody-drug conjugate (ADC) therapies using Redwood's SMARTag technology

Redwood Bioscience Inc.

U.S. / Private Biopharma

Licensor / Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Catalent Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensee / Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced